SE8004002L
(sv)
*
|
1980-05-29 |
1981-11-30 |
Arvidsson Folke Lars Erik |
Terapeutiskt anvendbara tetralinderivat
|
US4839104A
(en)
*
|
1987-06-11 |
1989-06-13 |
Pfizer, Inc. |
Process for preparing sertraline intermediates
|
US4777288A
(en)
*
|
1987-06-11 |
1988-10-11 |
Pfizer Inc. |
Process for preparing a 4,4-diphenylbutanoic acid derivative
|
FR2623802B1
(fr)
*
|
1987-11-26 |
1990-05-04 |
Lucien Laboratoires |
Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
|
US4855500A
(en)
*
|
1988-05-04 |
1989-08-08 |
Pfizer Inc. |
Process for preparing a ketimine
|
FR2632633B1
(fr)
*
|
1988-06-08 |
1991-04-05 |
Delalande Sa |
Procede de preparation de 4-aryl-1-tetralones
|
US4981870A
(en)
*
|
1989-03-07 |
1991-01-01 |
Pfizer Inc. |
Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
|
US4940731A
(en)
*
|
1989-08-30 |
1990-07-10 |
Pfizer Inc. |
Method of treating premature ejaculation using sertraline
|
DE69004529T2
(de)
*
|
1989-08-30 |
1994-02-24 |
Pfizer |
Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
|
US5130338A
(en)
*
|
1989-08-30 |
1992-07-14 |
Pfizer Inc. |
Method of treating chemical dependencies using sertraline
|
US4962128A
(en)
*
|
1989-11-02 |
1990-10-09 |
Pfizer Inc. |
Method of treating anxiety-related disorders using sertraline
|
FR2665443B1
(fr)
*
|
1990-08-03 |
1992-11-06 |
Lucien Laboratoires |
Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
|
US5082970A
(en)
*
|
1991-03-06 |
1992-01-21 |
Pfizer Inc. |
Process for recycling amine isomer
|
GB9114947D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline
|
GB9114948D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US5196607A
(en)
*
|
1992-02-14 |
1993-03-23 |
Pfizer Inc. |
Process for preparing ketone enantiomer
|
US5248699A
(en)
*
|
1992-08-13 |
1993-09-28 |
Pfizer Inc. |
Sertraline polymorph
|
US5288916A
(en)
|
1993-03-25 |
1994-02-22 |
Bend Research, Inc. |
Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
|
DE69406553T2
(de)
*
|
1993-11-30 |
1998-02-26 |
Pfizer Inc., New York, N.Y. |
Verfahren zur herstellung von chiralen tetralonen
|
US5597826A
(en)
|
1994-09-14 |
1997-01-28 |
Pfizer Inc. |
Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
|
US6410794B1
(en)
|
1994-12-16 |
2002-06-25 |
Uop Llc |
Process for preparation of pharmaceutically desired chiral tetralone from tetralones
|
US6455736B1
(en)
|
1994-12-16 |
2002-09-24 |
Uop Llc |
Process for preparation of pharmaceutically desired sertraline and sertraline analogs
|
AU5966196A
(en)
*
|
1995-06-08 |
1997-01-09 |
Eli Lilly And Company |
Methods of treating cold and allergic rhinitis
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
ATE192042T1
(de)
*
|
1995-08-16 |
2000-05-15 |
Lilly Co Eli |
Potenzierung von serotonin-wirkstoffresponz
|
US5734083A
(en)
*
|
1996-05-17 |
1998-03-31 |
Torcan Chemical Ltd. |
Sertraline polymorph
|
HU222341B1
(hu)
*
|
1996-12-18 |
2003-06-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
|
TW526195B
(en)
*
|
1997-06-10 |
2003-04-01 |
Novartis Ag |
Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
|
US20040208926A1
(en)
*
|
1997-07-01 |
2004-10-21 |
Pfizer Inc |
Solubilized sertraline compositions
|
US20030133974A1
(en)
*
|
1997-07-01 |
2003-07-17 |
Curatolo William John |
Encapsulated solution dosage forms of sertraline
|
JP2000514101A
(ja)
|
1997-07-01 |
2000-10-24 |
ファイザー・インク |
セルトラリン塩及びセルトラリンの持続性剤形
|
EP0928784B1
(en)
*
|
1997-12-11 |
2002-06-12 |
TORCAN CHEMICAL Ltd |
Sertraline polymorph having improved water solubility
|
IN191358B
(ko)
|
1998-01-16 |
2003-11-29 |
Pfizer Prod Inc |
|
WO1999046233A1
(fr)
*
|
1998-03-09 |
1999-09-16 |
Sumika Fine Chemicals Co., Ltd. |
Derives de l'alcool benzylique
|
AR018164A1
(es)
*
|
1998-03-18 |
2001-10-31 |
Ciba Sc Holding Ag |
Proceso para la preparacion de cis-ciclohexilidenaminas
|
FR2777000B1
(fr)
*
|
1998-04-01 |
2002-09-27 |
Catalys |
Procede de preparation de la sertraline racemique
|
PT957099E
(pt)
|
1998-04-15 |
2003-02-28 |
Pfizer Prod Inc |
Carboxamidas heterociclicas
|
US6054614A
(en)
*
|
1998-04-23 |
2000-04-25 |
Ciba Specialty Chemicals Corporation |
Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
|
HU226423B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing a 1(2h)-naphtalene-1-ylidene derivative
|
HU226424B1
(en)
*
|
1998-05-05 |
2008-12-29 |
Egis Gyogyszergyar Nyrt |
Process for producing enantiomer mixture for preparation of sertraline
|
IN182588B
(ko)
*
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
DE19830201A1
(de)
*
|
1998-07-07 |
2000-01-13 |
Boehringer Ingelheim Pharma |
Mittel mit antidepressiver Wirkung
|
US6727283B2
(en)
|
1998-10-13 |
2004-04-27 |
Pfizer Inc. |
Sertraline oral concentrate
|
JP3792514B2
(ja)
*
|
1998-10-13 |
2006-07-05 |
ファイザー・プロダクツ・インク |
セルトラリン経口濃縮物
|
IL132500A0
(en)
|
1998-10-29 |
2001-03-19 |
Pfizer Prod Inc |
Stereoselective microbial reduction of a racemic tetralone
|
AU1031500A
(en)
*
|
1998-11-03 |
2000-05-22 |
Dandy A/S |
Sucrose fatty acid esters for use as increased release of active ingredients
|
US6518284B2
(en)
*
|
1998-11-18 |
2003-02-11 |
Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. |
4-substituted piperidines
|
US6500987B1
(en)
*
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
EP1632472A1
(en)
*
|
1998-11-27 |
2006-03-08 |
Teva Pharmaceutical Industries Ltd |
Sertraline hydrochloride polymorphs
|
IL143311A0
(en)
*
|
1998-11-27 |
2002-04-21 |
Teva Pharma |
Sertraline hydrochloride polymorphs
|
WO2000051972A1
(en)
*
|
1999-03-01 |
2000-09-08 |
Pfizer Limited |
1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
US6593496B1
(en)
|
1999-06-09 |
2003-07-15 |
Pfizer Inc |
Process for preparing sertraline from chiral tetralone
|
EP1200387B1
(en)
*
|
1999-07-29 |
2004-04-21 |
Ciba SC Holding AG |
Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
|
US6495721B1
(en)
|
1999-08-09 |
2002-12-17 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride Form II and methods for the preparation thereof
|
IN185109B
(ko)
*
|
1999-09-01 |
2000-11-18 |
Torrent Pharmaceuticals Ltd |
|
DK174219B1
(da)
*
|
1999-10-27 |
2002-09-30 |
Gea Farmaceutisk Fabrik As |
Forbedret syntese af racemisk sertralin
|
TWI260315B
(en)
*
|
1999-10-29 |
2006-08-21 |
Ciba Sc Holding Ag |
Polymorphic forms of sertraline hydrochloride
|
US20050119351A1
(en)
*
|
1999-10-29 |
2005-06-02 |
Van Der Schaaf Paul A. |
Polymorphic forms of sertraline hydrochloride
|
US7442838B2
(en)
*
|
1999-10-29 |
2008-10-28 |
Ciba Specialty Chemicals Corp. |
Polymorphic forms of sertraline hydrochloride
|
ES2241680T3
(es)
*
|
1999-11-16 |
2005-11-01 |
Ciba Specialty Chemicals Holding Inc. |
Procedimiento para la preparacion de cetiminas.
|
MXPA02004854A
(es)
|
1999-11-16 |
2002-08-30 |
Ciba Sc Holding Ag |
Proceso para la preparacion de cetiminas.
|
US6380200B1
(en)
|
1999-12-07 |
2002-04-30 |
Pfizer, Inc. |
Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
|
PT1248605E
(pt)
*
|
1999-12-21 |
2007-03-30 |
Teva Pharma |
Novos polimorfos de cloridrato de sertralina, processos para a sua preparação, composições que os contêm e métodos para a sua utilização
|
JP2003518487A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動型積層薬物製剤
|
IN187170B
(ko)
|
2000-01-04 |
2002-02-23 |
Sun Pharmaceutical Ind Ltd |
|
HUP0300160A3
(en)
*
|
2000-03-14 |
2005-07-28 |
Teva Pharma |
Process for preparing (+)-cis-sertraline
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
IN192343B
(ko)
*
|
2000-05-26 |
2004-04-10 |
Ranbaxy Lab Ltd |
|
US6630504B2
(en)
|
2000-08-31 |
2003-10-07 |
Pfizer Inc. |
Phenoxyphenylheterocyclyl derivatives as SSRIs
|
EP1184372B1
(en)
*
|
2000-08-31 |
2006-04-26 |
Pfizer Limited |
Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs)
|
US6482440B2
(en)
|
2000-09-21 |
2002-11-19 |
Phase 2 Discovery, Inc. |
Long acting antidepressant microparticles
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
CA2448279A1
(en)
*
|
2001-05-31 |
2002-12-05 |
Orion Corporation Fermion |
Process for preparing sertraline hydrochloride polymorphic form ii
|
US6723878B2
(en)
|
2001-06-15 |
2004-04-20 |
Orion Corporation Fermion |
Method for preparing sertraline
|
CA2448499A1
(en)
*
|
2001-06-15 |
2002-12-27 |
Orion Corporation Fermion |
A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
|
EP1434763B1
(en)
*
|
2001-10-12 |
2018-01-17 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamyl vasopressin v1a antagonists
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2003251290A1
(en)
*
|
2002-04-29 |
2003-11-17 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
WO2004011413A1
(en)
*
|
2002-07-29 |
2004-02-05 |
Cipla Limited |
Sertraline
|
PL376832A1
(pl)
*
|
2002-11-07 |
2006-01-09 |
Torrent Pharmaceuticals Ltd. |
Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
|
US20040131672A1
(en)
*
|
2003-01-07 |
2004-07-08 |
Nilobon Podhipleux |
Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
WO2004087732A2
(en)
*
|
2003-03-11 |
2004-10-14 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
|
ES2242555T1
(es)
*
|
2003-04-14 |
2005-11-16 |
Teva Pharmaceutical Industries Limited |
Hidrogenacion de intermediarios de imina de sertralina con catalizadores.
|
EP1626950A4
(en)
*
|
2003-05-23 |
2007-05-23 |
Transform Pharmaceuticals Inc |
SERTRALINZUSAMMENSETZUNGEN
|
US20050070577A1
(en)
*
|
2003-07-03 |
2005-03-31 |
Pfizer Inc. |
Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
WO2005012224A1
(en)
*
|
2003-07-15 |
2005-02-10 |
Recordati Industria Chimica E Farmaceutica S.P.A. |
Sertraline hydrochloride form ii and methods for the preparation thereof
|
US7189876B2
(en)
*
|
2003-07-15 |
2007-03-13 |
Recordati Industria Chimica E Farmaceutica S.P.A. |
Methods for preparing sertraline hydrochloride polymorphs
|
HU227495B1
(en)
*
|
2003-07-21 |
2011-07-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Process for producing of imine intermediate
|
WO2005023752A2
(en)
*
|
2003-09-05 |
2005-03-17 |
Teva Pharmaceutical Industries Ltd. |
A recycling process for preparing sertraline
|
WO2005025563A1
(en)
*
|
2003-09-12 |
2005-03-24 |
Warner-Lambert Company Llc |
Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
CN103788089A
(zh)
*
|
2003-09-17 |
2014-05-14 |
詹森药业有限公司 |
作为血清素受体调节剂的稠合杂环化合物
|
RU2376279C2
(ru)
*
|
2003-11-04 |
2009-12-20 |
Сипла Лимитед |
Способ получения полиморфов ингибитора повторного захвата серотонина (варианты)
|
US20050250803A1
(en)
*
|
2003-11-26 |
2005-11-10 |
Pfizer Inc |
Combination of dopamine agonists and monoamine reuptake inhibitors
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
WO2005060968A1
(en)
|
2003-12-11 |
2005-07-07 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
WO2005117911A2
(en)
*
|
2004-05-06 |
2005-12-15 |
Cydex, Inc. |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
US7345201B2
(en)
*
|
2005-02-23 |
2008-03-18 |
Teva Pharmaceutical Industries, Ltd. |
Processes for preparing sertraline
|
AU2006227199A1
(en)
|
2005-03-22 |
2006-09-28 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
JP2006265169A
(ja)
*
|
2005-03-24 |
2006-10-05 |
Tokuyama Corp |
アルキリデンコハク酸化合物の製造方法
|
GB0507090D0
(en)
*
|
2005-04-07 |
2005-05-11 |
Sandoz Ag |
Process for preparing polymorphic form ll of sertraline hydrochloride
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GT200600165A
(es)
*
|
2005-04-22 |
2007-03-14 |
|
Derivados dihidrobenzofuranos y usos de los mismos
|
PE20061297A1
(es)
*
|
2005-04-22 |
2006-12-24 |
Wyeth Corp |
Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
|
MX2007012883A
(es)
|
2005-04-22 |
2007-12-10 |
Wyeth Corp |
Derivados de dihidrobenzofurano y usos de los mismos.
|
US20060252825A1
(en)
*
|
2005-04-22 |
2006-11-09 |
Wyeth |
Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
BRPI0610036A2
(pt)
|
2005-04-22 |
2010-05-18 |
Wyeth Corp |
derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
|
US20070260090A1
(en)
*
|
2005-06-03 |
2007-11-08 |
Hetero Drugs Limited |
Highly Steroselective Synthesis of Sertraline
|
WO2007008317A2
(en)
*
|
2005-06-09 |
2007-01-18 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of sertraline hydrochloride form i
|
EP1896002A4
(en)
*
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
|
AU2006269231A1
(en)
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
JP5328349B2
(ja)
*
|
2005-07-19 |
2013-10-30 |
アゼヴァン ファーマスーティカルズ,インコーポレイテッド |
ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
CN101426372A
(zh)
*
|
2006-01-06 |
2009-05-06 |
塞普拉柯公司 |
基于四氢萘酮的单胺再摄取抑制剂
|
WO2007087387A1
(en)
*
|
2006-01-23 |
2007-08-02 |
Teva Pharmaceutical Industries Ltd. |
A recycling process for preparing sertraline
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
AU2007231011A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
WO2007119247A2
(en)
*
|
2006-04-17 |
2007-10-25 |
Unichem Laboratories Limited |
Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
|
TR200808115T1
(tr)
*
|
2006-04-28 |
2009-03-23 |
Sandoz Ag |
4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
US7518019B2
(en)
*
|
2006-06-01 |
2009-04-14 |
Hetero Drugs Limited |
Processes for preparing sertraline hydrochloride crystalline forms
|
WO2007146796A2
(en)
*
|
2006-06-13 |
2007-12-21 |
Ramot At Tel-Aviv University Ltd. |
Antiproliferative compounds, compositions and methods of use
|
US7893053B2
(en)
*
|
2006-06-16 |
2011-02-22 |
Theracos, Inc. |
Treating psychological conditions using muscarinic receptor M1 antagonists
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
US20060257475A1
(en)
*
|
2006-08-17 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Stable Sertraline Hydrochloride Formulation and Method
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
FR2909376A1
(fr)
*
|
2006-11-30 |
2008-06-06 |
Cerep Sa |
Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
|
US20080167363A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc |
Modulation of Neurogenesis By Melatoninergic Agents
|
US20080171750A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation Of Neurogenesis With Use of Modafinil
|
CA2594198A1
(en)
*
|
2007-07-20 |
2009-01-20 |
Apotex Pharmachem Inc. |
A novel process for the preparation of sertraline hydrochloride form ii
|
US20090062399A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sertraline
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
EP2291181B9
(en)
|
2008-04-18 |
2013-09-11 |
University College Dublin National University Of Ireland, Dublin |
Captodiamine for the treatment of depression symptoms
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US9260413B2
(en)
*
|
2010-03-04 |
2016-02-16 |
Merck Sharp & Dohme Corp. |
Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
|
EP2380595A1
(en)
|
2010-04-19 |
2011-10-26 |
Nlife Therapeutics S.L. |
Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
|
US8440655B2
(en)
|
2010-06-21 |
2013-05-14 |
Theracos, Inc. |
Combination therapy for the treatment of diabetes
|
RU2623209C9
(ru)
|
2010-07-01 |
2018-01-22 |
Азеван Фармасьютикалз, Инк. |
Способы лечения посттравматического стрессового расстройства
|
JP2014508187A
(ja)
|
2011-03-17 |
2014-04-03 |
ルピン・リミテッド |
選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
|
KR101340270B1
(ko)
*
|
2011-11-10 |
2013-12-10 |
보령제약 주식회사 |
(+)-시스-서트랄린의 선택적인 제조방법
|
KR20150070102A
(ko)
*
|
2012-10-18 |
2015-06-24 |
에프. 호프만-라 로슈 아게 |
mGluR5 수용체 활성의 조절제로서 에틴일 유도체
|
RU2742773C2
(ru)
|
2014-03-28 |
2021-02-10 |
Азеван Фармасьютикалз, Инк. |
Композиции и способы лечения нейродегенеративных заболеваний
|
US10266481B2
(en)
|
2014-06-20 |
2019-04-23 |
Council Of Scientific & Industrial Research |
Organocatalytic asymmetric synthesis of antidepressants
|
EP3180337B1
(en)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
JP6667092B2
(ja)
*
|
2014-08-11 |
2020-03-18 |
ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC |
ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
|
EP3180340B1
(en)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
EP3180345B1
(en)
*
|
2014-08-11 |
2018-10-10 |
Hydra Biosciences, Inc. |
Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
|
JP7405341B2
(ja)
|
2015-09-21 |
2023-12-26 |
エス.シー. ジョンソン アンド サン、インコーポレイテッド |
混合及び散布のシステム
|
AU2018333051B2
(en)
|
2017-09-15 |
2024-03-21 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|
WO2020043716A1
(en)
|
2018-08-27 |
2020-03-05 |
Katholieke Universiteit Leuven |
Pharmacological targeting of de novo serine/glycine synthesis
|